CAMKK2 and metabolic dysfunction-associated steatotic liver disease: In addition, CAMKK2 inhibition protects mice from developing metabolic syndrome shown through a decrease in blood glucose and insulin resistance as well as regression of nonalcoholic fatty liver disease (NAFLD) [20,21,22].